Table 1: General Demographic Data
Gender

5 Male

11 Female

Race

11 White (nonhispanic)

5 Black

Primary language

14 English

2 Spanish

Mean Age

43.4 +/- 7.2 years

2 Hispanic

Figure 2: Psychiatric Medication Adjustments During Treatment with PEG-IFN
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Hepatitis C virus (HCV) is a major public health problem in the United States with an
estimated 4 million people infected[1]. The treatment of this disease with peginterferon
alfa 2a (PEG-IFN) is often complicated by a variety of neuropsychiatric symptoms. Patients
with HCV with a previous psychiatric diagnosis often have a more complicated and
difficult treatment course associated with PEG-IFN. The purpose of this study was to
evaluate the effects of PEG-IFN on the course of psychiatric illness in patients with
established psychiatric diagnoses. In a clinical study of HCV patients without preexisting
psychiatric diagnoses who received PEG-IFN treatment, 23% became depressed during
treatment[2]. However, there are few studies addressing outcomes in Hepatitis C patients
who also have an established psychiatric condition. Preexisting psychiatric
comorbidities that are associated with Hepatitis C are not absolute contraindications for
treatment with PEG-IFN. Unfortunately, many patients are denied PEG-IFN therapy for this
reason, and many of those who do initiate treatment do not have access to the multidisciplinary care that is needed to effectively manage psychiatric side effects. In a
veteran’s hospital study of 690 hepatitis C patients with psychiatric comorbidities, only
33 received interferon-alpha therapy over a two year period[3]. Currently, this subgroup
of Hepatitis C patients has been underserved by the medical community.

Of the 16 patients with prior psychiatric diagnoses that underwent PEG-IFN treatment, 6
ultimately needed to stop treatment early due to lack of virologic response or medical
side effects. These medical side effects did not include psychiatric complications. The
other 10 have recently finished or are finishing treatment as of March 2006.
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The Hepatitis C Clinic was established in early 2004 and meets monthly. Internal medicine
residents are precepted by an attending gastroenterologist and psychiatrist and are
supported by a registered nurse coordinator. Treatment for HCV with PEG-IFN and
ribavirin is guided by evidence-based protocols within the confines of managed care
formularies. Data was gathered retrospectively through chart review for patients with
preexisting psychiatric diagnoses and their subsequent treatment outcomes. Patients
without prior psychiatric disease and those who weren’t treated with PEG-IFN and
ribavirin were excluded from this analysis.

No change in mood
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Schizoaffective Disorder
Medication Adjustments

* Ten had a substance abuse disorder in conjunction with their psychiatric disorder

Table 2: Psychiatric Demographic Data

One patient had a psychiatric hospitalization due to bizarre behavior after taking a
combination of narcotics and benzodiazepines, but PEG-IFN was not discontinued due to
this hospitalization. No patients experienced suicidal ideations and there were no suicide
attempts.

# patients
Thirty-eight patients have been evaluated and ultimately 18 patients have declined
treatment due to personal or logistical reasons. There were no psychiatric reasons for
declining treatment. Of the 20 patients who received treatment, 4 patients had no
psychiatric diagnosis and 16 patients had prior psychiatric diagnoses.

No prior psychiatric hospitalizations

9

One prior psychiatric hospitalization

2

Greater than two prior psychiatric hospitalizations

5

Residents of state hospital system

5

Prior suicide attempts (not in 6 mos. Prior to treatment)

6

In an attempt to treat under-insured and uninsured patients with Hepatitis C via a
resident-initiated, multidisciplinary clinic, there were no significant changes in
psychiatric symptoms of the 16 patients with prior psychiatric diagnosis who underwent
treatment with PEG-IFN. The lack of significant psychiatric side effects in this population
of patients is surprising, given the severity of psychiatric illness in these patients at the
onset of treatment. This suggests that in an integrative clinic consisting of an attending
gastroenterologist, attending psychiatrist, residents, and nurse coordinator can safely
manage psychiatric comorbidities and PEG-IFN treatment to expand access to care.
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